Featured Featured Peptide APIs & Custom Syntheses (Batch 01)
Explore our industrial-grade synthesized peptides, custom analogs, and active pharmaceutical ingredients manufactured under rigorous ISO/GMP quality frameworks.
Executive Summary: Thymosin Alpha 1 (Ta1) Industrial Profile
Thymosin Alpha 1 (Ta1), a 28-amino acid peptide derived from prothymosin alpha, plays a pivotal role in modern immunomodulatory therapeutics. Identified chemically by CAS Registry Number 62304-98-7, Ta1 triggers baseline immunological responses through the direct activation of Toll-like receptor (TLR)-7 and TLR-9 signaling pathways in dendritic cells. As global demand for robust biological response modifiers expands across oncology, chronic viral infectious diseases, and vaccine adjuvant formulation, securing a validated, scalable, and highly reproducible custom Ta1 peptide manufacturer has become a top strategic imperative for global biopharmaceutical procurement networks.
Our manufacturing platform combines solid-phase peptide synthesis (SPPS) mastery with proprietary continuous-flow liquid-phase purification technologies. By controlling secondary structure aggregation and truncations—inherent bottlenecks in 28-mer peptide chains—we guarantee industrial production yields with purity metrics reaching up to >99.5% by RP-HPLC and bacterial endotoxin levels maintained below <0.01 EU/mg.
Biochemical Specification Standard for Custom Ta1 Synthesis
| Parameter | Analytical Specification | Testing Methodology |
|---|---|---|
| Chemical Name | Thymosin Alpha 1 (N-Acetyl-L-alpha-aspartyl-L-alpha-glutamyl...) | IUPAC Standard Nomenclature |
| CAS Registry Number | 62304-98-7 | CAS Database Verification |
| Molecular Formula / Mass | C129H215N33O55 / 3108.3 g/mol | High-Resolution ESI-MS / MALDI-TOF |
| Primary Sequence | Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH | Edman Degradation / MS-MS Sequencing |
| Purity (Grade Options) | 95%, 98%, 99.0%, 99.5% (Customizable) | Reverse-Phase HPLC (RP-HPLC) |
| Residual Solvents | Acetonitrile < 410 ppm, DMF < 880 ppm, Ether < 5000 ppm | Headspace Gas Chromatography (HS-GC) |
| Bacterial Endotoxins | < 0.05 EU/mg (Research) | < 0.01 EU/mg (Injectable CDMO Grade) | Chromogenic LAL Kinetic Assay |
Global Commercial Status & Industrial Application Landscape
The international market for Thymosin Alpha 1 has transitioned from niche immunomodulation applications to high-volume integration within broad systemic treatment protocols. Historically prescribed for chronic Hepatitis B and C therapeutic interventions, contemporary therapeutic trends leverage Ta1 as a potent adjuvant in checkpoint-inhibitor cancer immunotherapies (e.g., anti-PD-1 / anti-PD-L1 combinations) and severe sepsis management protocols.
Oncology Adjuvant Therapy
Ta1 enhances endogenous cell-mediated immunity by inducing T-cell maturation (CD4+/CD8+ upregulation) and activating natural killer (NK) cell cytotoxicity. Contract formulation partners utilize our high-purity Ta1 active pharmaceutical ingredients (APIs) to mitigate chemotherapy-induced immunosuppression in non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC).
Severe Sepsis & Critical Care
Clinical investigations demonstrate that Ta1 administration attenuates hyper-inflammatory cascades while restoring functional lymphocyte counts in septic patients. Our CDMO pipeline supplies ultra-low endotoxin bulk powders optimized for rapid reconstitution in ICU-grade parenteral delivery systems.
Vaccine Potentiation & Antiviral Research
Serving as a molecular adjuvant, Ta1 amplifies antibody titers in immunocompromised populations, such as elderly patients receiving influenza or therapeutic viral vaccines. We support customized peptide conjugation (e.g., lipid-moiety additions, PEGylation) to extend in vivo biological half-life.
Technical Roadmap: Overcoming Synthesis Bottlenecks in 28-Mer Chains
Synthesizing a 28-amino acid peptide with multiple acidic residues (Aspartic Acid and Glutamic Acid repeat clusters) presents significant chemical challenges. Beta-elimination, aspartimide formation, and steric hindrance during long-chain assembly often lead to truncated impurities (e.g., des-Glu or des-Asp sequences) that closely mimic the physical profile of full-length Ta1, rendering conventional purification inefficient.
Our Proprietary 4-Stage Synthesis Engineering Strategy
- Pseudoproline Dipeptide Integration: By embedding hydrophobic pseudoproline dipeptides at strategic turn-locations (such as Thr-Ser junctions) during Solid-Phase Synthesis, we disrupt secondary beta-sheet aggregation on resin beads, elevating step-wise coupling efficiencies to >99.2%.
- Racemization-Free Coupling Chemistry: Utilizing DIC/Oxyma Pure coupling cocktails in place of traditional HBTU/HOBt reagents minimizes alpha-carbon racemization across acid-labile glutamyl residues.
- Two-Dimensional Preparative RP-HPLC: Our purification architecture employs a dual-stage separation paradigm: Stage 1 uses orthogonal C18 stationary phases under acidic pH conditions (0.1% TFA) to resolve major deletion sequences, followed by Stage 2 under neutral/slightly basic ammonium acetate conditions to cleanly separate closely related diastereomers.
- Aseptic Lyophilization Control: Final step flash-freezing under Class 100 (ISO 5) cleanroom conditions guarantees uniform cake cake structure, rapid solubility reconstitutions, and moisture content control strictly maintained below <3.0%.
China Supply Chain Resilience & Scale Advantage
As an established China-based peptide API manufacturer, our operational infrastructure leverages an integrated upstream-to-downstream industrial ecosystem. China synthesizes over 70% of the world's raw protected amino acids (Fmoc/Boc derivatives), coupling agents, and specialized synthesis resins. By locating our production campus adjacent to high-capacity chemical clusters, we eliminate supply chain vulnerabilities that frequently disrupt Western manufacturing operations.
Upstream Raw Material Integration
Direct backward integration into raw protected amino acid synthesis guarantees lot-to-lot traceability and immunizes our clients against global raw material price inflation and allocation shortages.
Automated Reactor Array Scaling
Our facility operates solid-phase reactors ranging from 50L pilot scale up to 1000L industrial automated synthesis vessels. This scalable footprint enables batch outputs from 500 grams up to multi-kilogram commercial lots per single production cycle.
Cold-Chain & Freight Security
We maintain direct relationships with validated global biopharmaceutical logisticians. Temperature-monitored, validated dry-ice packaging units (-20°C and -80°C requirements) ensure total structural stability from our Hangzhou factory floor to destination laboratories worldwide.
Localized Application Scenarios & Formulation Flexibility
Depending on regional therapeutic regulations and targeted patient pathways, custom Ta1 applications require tailored dosage form engineering. Our CDMO technical services team assists partners in designing customized delivery vehicles:
- Parenteral Lyophilized Vials: Standard clinical packaging in 1.6mg, 3.2mg, and 5.0mg dosages with mannitol or trehalose lyoprotectant matrices optimized for rapid reconstitution with sterile water for injection (WFI).
- Intranasal Aerosol Delivery Systems: Specialized research formulations leveraging bioadhesive polymers to facilitate mucosal absorption, avoiding first-pass enzymatic degradation in localized antiviral research.
- Sustained-Release Microspheres (PLGA Matrix): Bioerodible poly(lactic-co-glycolic acid) encapsulation services that provide continuous release profiles over 14-to-30-day windows, eliminating the need for daily patient subcutaneous injections.
- Custom Conjugation Services: Covalent attachment to fluorescent tags (FITC, Cy5), biotinylation, or cell-penetrating peptides (CPPs) for preclinical receptor tracking and bio-imaging investigations.
Localization Support & Regulatory Compliance Framework
Navigating international drug filings requires comprehensive quality control documentation. To ensure seamless customer regulatory submissions across NMPA, US FDA, EMA, and PMDA, our quality assurance department delivers complete analytical dossier packages built strictly around ICH guidelines:
Regulatory Documentation (CTD Format)
We provide comprehensive Type II Drug Master File (DMF) documentation, including detailed synthesis route flowcharts, residual solvent analyses, structural characterization (NMR, FT-IR, MS), and impurities profiling.
ICH Stability Protocol Testing
Accelerated (40°C ± 2°C / 75% RH ± 5% RH) and long-term (5°C ± 3°C and -20°C ± 5°C) real-time stability testing packages are compiled to establish validated shelf-life profiles for your target market.
Full Batch Audit Traceability
Every commercial batch is supplied with a fully traceable Certificate of Analysis (CoA), mass spectra data, analytical HPLC chromatograms, heavy metals analysis, and residual water determination (Karl Fischer titration).
Frequently Asked Questions (Technical & Procurement Q&A)
Answers to crucial technical and logistics questions surrounding custom Thymosin Alpha 1 synthesis and bulk API procurement.
For custom synthesis specifications requiring novel conjugation or non-standard purity targets (e.g., 99.5%+), pilot production timelines range from 2 to 3 weeks. Bulk commercial API orders from our validated library stock ship within 3 to 5 business days globally via temperature-controlled biopharma cold-chain channels.
Thymosin Alpha 1 exhibits optimal solubility in sterile aqueous buffers near neutral pH (pH 6.8 - 7.4). During our custom lyophilization processing, we adjust the counter-ion composition (offering Acetate, Trifluoroacetate, or Hydrochloride salt forms) to maximize solubility parameters tailored to your vehicle substrate.
Yes. We offer seamless tech-transfer from non-GMP research batches to full cGMP manufacturing suites. Our cleanroom facilities follow strict FDA 21 CFR Part 211 standards, equipped with isolated HVAC infrastructure, validated CIP/SIP automated systems, and full environmental monitoring control.
While standard SPPS cleavages yield Trifluoroacetate (TFA) salts, residual TFA can induce cell toxicity in preclinical models. We offer specialized ion-exchange chromatography to convert TFA salts into bio-friendly Acetate (AcO-) or Sodium salt forms, ensuring TFA residual levels remain strictly below <1.0% or non-detectable (<0.1%).
Simply select a product from our catalogue or click any inquiry link on this page to share your project specifications (target quantity, purity requirement, salt form, and desired delivery date). Our technical project managers will provide a comprehensive project feasibility quote within 24 hours.
Complementary Therapeutic Peptides & Active Ingredients (Batch 02)
Discover our expanded catalog of high-purity generic peptides, therapeutic analogs, and custom metabolic active ingredients engineered for global distribution.
Partner with a Globally Recognized Ta1 Peptide CDMO Specialist
Whether you require high-purity research reference standards, pilot scale validation batches, or multi-kilogram commercial API contracts, our technical team stands ready to support your development program. Contact us today to access technical dossiers, COAs, and competitive commercial quotes.